Latest Us Market News

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

Foley Wines reported a 258% surge in net profit for FY2026 despite a 5.4% decline in bottled sales revenue, driven by a premiumisation strategy and cost controls.

Saluda Medical delivered FY26 revenue of US$90.2 million, beating guidance with strong US and international growth, while reporting a flat net loss of US$149.6 million amid ongoing heavy investment. The company’s FDA approval of its CAP24 paddle lead opens a new US surgical market segment.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.

Wiseway Group delivered 10.1% revenue growth to $205.6 million in FY26, led by a 22.2% surge in its eCommerce Solutions division, while maintaining EBITDA margins amid cost discipline. The Group declared a fully franked final dividend of 0.6 cents per share.

Future Generation Global's half-year profit fell sharply as its portfolio lagged global benchmarks, yet it boosted its fully franked interim dividend reflecting confidence in its income sustainability.

Epiminder Limited reported a $42.7 million loss for FY26, driven by clinical trial and product development costs following a $125 million IPO. The company progresses its FDA-approved Minder implantable EEG monitor with a pivotal US trial and next-gen device on track for 2028 launch.

PolyNovo reported a 16.1% rise in FY26 revenue to AUD 150 million, driven by strong global sales and manufacturing expansion, yet net profit fell 44% due to a significant asset write-off from an R&D centre fire and lower tax benefits.

Scales Corporation delivered a record first half in 2026 with revenues soaring 105% to NZ$762.1 million and underlying EBITDA up 18% to NZ$102.2 million. The diversified agribusiness raised its full year profit guidance despite challenges in Europe and the Middle East.

NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.

ARB Corporation's FY2026 results show a 3.8% revenue dip and 5.2% profit decline amid challenging 4x4 sales, while international expansion and engineering investment underpin future growth.

Genetic Signatures narrowed its FY2026 net loss by 30% to $14 million amid a strategic overhaul, signing a key 10-year supply deal with Denmark’s Hvidovre Hospital and resetting its US market approach.